With several vaccine candidates showing promise, UNICEF, in collaboration with the PAHO Revolving Fund, will lead efforts to procure and supply doses of Covid-19 vaccines on behalf of the COVAX Facility for 92 low- and lower middle-income countries whose vaccine purchases will be supported by the mechanism through the Gavi COVAX AMC as well as a buffer stockpile for humanitarian emergencies.
Henrietta Fore, UNICEF Executive Director said: “This is an all-hands on deck partnership between governments, manufacturers and multilateral partners to continue the high-stakes fight against the Covid-19 pandemic.”
Fore said UNICEF is leveraging its unique strengths in vaccine supply to make sure that all countries have safe, fast and equitable access to the initial doses when they are available.
Gavi CEO, Dr Seth Berkley, said that UNICEF has been critical partner in the Alliance’s success over the last two decades – helping to reach more than half of the world’s population with life-saving vaccines.
Dr Berkley said: “This expertise and experience will be important in ensuring that COVAX – as a global effort to procure and deliver safe and effective Covid-19 vaccines, on an accelerated timeframe, and at an unprecedented scale – can protect the most at-risk, wherever they may be in the world. Together we can work to end the acute stage of this pandemic, including its devastating impact on individuals, communities, and economies.”
UNICEF will also serve as procurement coordinator to support procurement by 80 higher-income economies, which have expressed their intent to participate in the COVAX Facility and would finance the vaccines from their own public finance budgets.
It will undertake these efforts in close collaboration with WHO, Gavi, CEPI, PAHO, World Bank, the Bill and Melinda Gates Foundation and other partners. The COVAX Facility is open to all countries to ensure that no country is left without access to a future Covid-19 vaccine.
UNICEF is the largest single vaccine buyer in the world, procuring more than 2 billion doses of vaccines annually for routine immunization and outbreak response on behalf of nearly 100 countries.
It is the main procurement partner of Gavi, the Vaccine Alliance, which over the last 20 years has reached more than 760 million children with life-saving vaccines, preventing more than 13 million deaths. UNICEF will use its market shaping and procurement expertise to coordinate the procurement and supply of Covid-19 vaccines for the COVAX Facility.
In response to an expression of interest that UNICEF issued in June on behalf of the COVAX Facility, 28 manufacturers with production facilities in 10 countries shared their annual production plans for Covid-19 vaccines through 2023.
According to the timelines the manufacturers indicated, the span from development to production could be one of the fastest scientific and manufacturing leaps in history.
A UNICEF market assessment, developed by compiling information submitted by vaccine manufacturers along with publicly available data, revealed that manufacturers are willing to collectively produce unprecedented quantities of vaccines over the coming 1-2 years.
However, manufacturers signaled that investments to support such large-scale production of doses would be highly dependent on, among other things, whether clinical trials are successful, advance purchase agreements are put in place, funding is confirmed, and regulatory and registration pathways are streamlined.
The assessment also illustrates, among other things, manufacturers’ responsiveness to the COVAX Facility’s design and objectives—a key pillar of the ACT-Accelerator initiative, which is a new, groundbreaking global collaboration to accelerate the development and equitable distribution of vaccines, diagnostics and therapeutics to address the Covid-19 pandemic across countries of all income levels.
Currently under development by WHO, the COVAX allocation framework will guide how and where UNICEF, PAHO and other procurers working on behalf of participating countries supply Covid-19 vaccines that are secured by the Facility.
Initial dose allocations are expected to be scaled to enable countries to vaccinate health and social workers, followed by subsequent tranches of vaccine doses that would enable participating countries to vaccinate populations at higher risk of critical Covid-19 disease.